BioMarin appeases activist investor by adding three directors, reviewing business

A cooperation agreement with Elliott Investment Management is a temporary measure — the BioMarin board will return to 11 directors next spring, for example — but its mandated review of the drugmaker’s business could be far-reaching.
Click here to view original post

Advertisement — Advertise with Biotech Networks